Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy
Frontiers in Pharmacology · 26.03.2026 · 17
DOI: 10.3389/fphar.2026.1744580 ↗Kurz gefasst
Editorial in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.03.2026. Verfasst von Renwang Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lung Cancer Surgery, Center of Thoracic Surgery, Tianjin Medical University General Hospital, Tianjin, China. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death, and immune 21 checkpoint inhibitors (ICIs) have revolutionized its treatment by reactivating the immune system to tumor cells [1,2] . Despite significant improvements in patient outcomes, ICIs present 23 several key challenges: inconsistent efficacy across populations, complex resistance mechanisms, 24 and treatment-related toxicities [2,3]
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Lung Cancer Surgery, Center of Thoracic Surgery, Tianjin Medical University General Hospital, Tianjin, China.
- Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Central Laboratory, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
- Cardiothoracic Surgery Department, Weill Cornell Medicine, New York, NY, United States.
- Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, R., Meng, Y., & Rahouma, M. (2026). Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1744580
Vancouver
Liu R, Meng Y, Rahouma M. Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1744580
BibTeX
@article{Liu2026,
author = {Liu, Renwang and Meng, Yiming and Rahouma, Mohamed},
title = {Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1744580}
}
EUVIMED